Dominguez Wealth Management Solutions Inc. Increases Position in Johnson & Johnson (NYSE:JNJ)

Dominguez Wealth Management Solutions Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 23,936 shares of the company’s stock after purchasing an additional 237 shares during the quarter. Johnson & Johnson accounts for about 3.0% of Dominguez Wealth Management Solutions Inc.’s investment portfolio, making the stock its 7th biggest position. Dominguez Wealth Management Solutions Inc.’s holdings in Johnson & Johnson were worth $3,786,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Consilio Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson by 5.6% during the 1st quarter. Consilio Wealth Advisors LLC now owns 1,885 shares of the company’s stock worth $298,000 after purchasing an additional 100 shares during the period. Park Place Capital Corp increased its holdings in shares of Johnson & Johnson by 63.5% during the 1st quarter. Park Place Capital Corp now owns 3,526 shares of the company’s stock worth $558,000 after purchasing an additional 1,369 shares during the period. Claro Advisors LLC increased its holdings in shares of Johnson & Johnson by 7.1% during the 1st quarter. Claro Advisors LLC now owns 23,379 shares of the company’s stock worth $3,698,000 after purchasing an additional 1,545 shares during the period. Talbot Financial LLC boosted its position in shares of Johnson & Johnson by 2.3% during the 1st quarter. Talbot Financial LLC now owns 91,459 shares of the company’s stock valued at $14,468,000 after acquiring an additional 2,063 shares in the last quarter. Finally, Miracle Mile Advisors LLC boosted its position in shares of Johnson & Johnson by 10.8% during the 1st quarter. Miracle Mile Advisors LLC now owns 65,280 shares of the company’s stock valued at $10,327,000 after acquiring an additional 6,383 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $146.03 on Wednesday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm’s 50 day moving average is $148.09 and its 200-day moving average is $153.97. The firm has a market capitalization of $351.45 billion, a price-to-earnings ratio of 9.10, a PEG ratio of 2.43 and a beta of 0.52. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same period in the prior year, the business earned $2.68 earnings per share. Johnson & Johnson’s quarterly revenue was up 2.3% on a year-over-year basis. Sell-side analysts forecast that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.40%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s payout ratio is 30.92%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, Bank of America reduced their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $174.07.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.